Harel Insurance Investments & Financial Services Ltd. Buys 792 Shares of Edwards Lifesciences Co. (NYSE:EW)

Harel Insurance Investments & Financial Services Ltd. lifted its stake in Edwards Lifesciences Co. (NYSE:EW) by 26.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,784 shares of the medical research company’s stock after purchasing an additional 792 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.’s holdings in Edwards Lifesciences were worth $350,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Edwards Lifesciences by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 52,964,394 shares of the medical research company’s stock valued at $5,061,277,000 after acquiring an additional 600,994 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Edwards Lifesciences by 9.5% in the 1st quarter. Bank of New York Mellon Corp now owns 18,973,304 shares of the medical research company’s stock valued at $1,813,089,000 after acquiring an additional 1,644,869 shares in the last quarter. Brown Advisory Inc. lifted its position in Edwards Lifesciences by 20.1% in the 4th quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock valued at $1,386,333,000 after acquiring an additional 3,048,274 shares in the last quarter. Wellington Management Group LLP lifted its position in Edwards Lifesciences by 2.4% in the 4th quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company’s stock valued at $1,283,098,000 after acquiring an additional 393,109 shares in the last quarter. Finally, Norges Bank bought a new position in Edwards Lifesciences in the 4th quarter valued at approximately $648,540,000. 79.46% of the stock is owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $87.54, for a total value of $437,700.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $4,108,777.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $87.54, for a total value of $437,700.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at $4,108,777.44. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bernard J. Zovighian sold 8,617 shares of Edwards Lifesciences stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $87.68, for a total value of $755,538.56. Following the completion of the transaction, the chief executive officer now owns 68,218 shares of the company’s stock, valued at approximately $5,981,354.24. The disclosure for this sale can be found here. Insiders sold 23,617 shares of company stock valued at $1,990,089 in the last 90 days. Insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

EW has been the topic of several analyst reports. TD Cowen cut Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their price objective for the company from $100.00 to $70.00 in a research report on Thursday, July 25th. Stifel Nicolaus decreased their target price on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a research note on Thursday, July 25th. Piper Sandler decreased their target price on shares of Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating for the company in a research note on Thursday, July 25th. Robert W. Baird lowered shares of Edwards Lifesciences from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $102.00 to $70.00 in a research note on Thursday, July 25th. Finally, Wolfe Research upgraded shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research note on Monday, July 29th. Fourteen research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $82.10.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded up $1.49 during mid-day trading on Tuesday, hitting $69.75. The stock had a trading volume of 2,017,558 shares, compared to its average volume of 4,064,975. The firm has a market capitalization of $42.03 billion, a P/E ratio of 29.42, a P/E/G ratio of 2.57 and a beta of 1.11. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. The firm’s 50 day moving average is $80.41 and its 200 day moving average is $85.82. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The business had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. During the same quarter in the prior year, the firm earned $0.66 EPS. The business’s revenue was up 6.7% on a year-over-year basis. On average, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.71 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.